慢性粒单核细胞白血病中共病和突变(包括单打击和多打击TET2突变)与结局的关系——一项基于人群的研究
该研究基于149例连续患者的群体队列,探讨慢性粒单核细胞白血病(CMML)的疾病特征、共病、突变与总生存(OS)的关系。TET2突变(TET2MT)患者血红蛋白更高、白细胞增多更少且OS更长,多打击TET2MT结局最佳(HR 0.55,CI 0.35-0.88,p<0.05)。包含TET2MT数量的预后模型在预测OS方面优于CPSS-Mol。
要点
- 多打击TET2MT与最佳结局相关(HR 0.55,CI 0.35-0.88,p<0.05)。
- TET2MT患者血红蛋白更高、白细胞增多更少且OS更长。
- 包含TET2MT数量的模型预测OS优于CPSS-Mol。
核心结论
- TET2突变状态,尤其是多打击TET2MT,定义了特定的CMML表型,应考虑纳入未来的预后评分。
研究设计与样本
- 基于人群的队列研究,纳入149例连续CMML患者。
主要发现
- 与无TET2MT(TET2WT)相比,TET2MT与更高的血红蛋白、更少的白细胞增多和更长的OS相关,尽管TET2MT患者年龄显著更大。
- 多打击TET2MT患者结局最佳(HR 0.55,CI 0.35-0.88,p<0.05)。
- 多打击TET2MT与较低的乳酸脱氢酶和较少的单核细胞增多相关,提示多打击TET2MT为独立的疾病实体。
- 33.6%的患者存在自身免疫性疾病(AID),与任何突变均无关联。
- 多变量分析显示,TET2MT数量是与改善OS相关的独立因素,而RUNX1MT、骨髓增殖性CMML(CMML-MP)、ECOG>0和输血依赖仍为显著的不良因素。
临床怎么用
- 作者认为,TET2突变状态,尤其是多打击TET2MT,定义了特定的CMML表型,应考虑纳入未来的预后评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To explore the relation between disease characteristics, comorbidities, mutations and overall survival (OS) in chronic myelomonocytic leukaemia (CMML), we collected data from a population-based cohort of 149 consecutive patients. TET2 mutation (TET2MT) was associated with higher haemoglobin, less leucocytosis and longer OS compared to no TET2MT (TET2WT), despite patients being significantly older. Patients with multihit TET2MT had the most favourable outcome (HR 0.55, CI 0.35-0.88, p < 0.05). Multihit TET2MT was associated with lower lactate dehydrogenase and less monocytosis, indicating multihit TET2MT as a separate disease entity. Autoimmune disease (AID) was present in 33.6% of patients, with no association to any mutations. In multivariable analysis, the number of TET2MT was demonstrated to be an independent factor associated with improved OS, and RUNX1MT, myeloproliferative CMML (CMML-MP), ECOG >0 and transfusion dependence remained significant adverse factors. Internal validation including cross-validation and correction for optimism consistently demonstrated that a prognostic model containing the number of TET2MT, RUNX1, CMML-MP, ECOG >0 and transfusion dependence showed better calibration, discrimination and overall performance than CPSS-Mol in predicting OS. Importantly, the addition of TET2 mutation status to CPSS-Mol also improved the CPSS-Mol score performance. Taken together, TET2MT status, especially multihit TET2MT, defines a specific CMML phenotype and should be considered in future prognostic scores.
引用
- Kynning MK, Westerberg E, Forsell L, et al. Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study. Br J Haematol. 2025. PMID: 41287892. doi:10.1111/bjh.70264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。